Skip to main content

Table 2 Summary of best response

From: HAIC Combined with lenvatinib plus PD-1 versus lenvatinib Plus PD-1 in patients with high-risk advanced HCC: a real-world study

 

RECIST 1.1

 

mRECIST

HAIC-LEN-PD1

LEN-PD1

P-value

 

HAIC-LEN-PD1

LEN-PD1

P-value

Overall Reponse

n = 103

n = 61

  

n = 103

n = 61

 

CR

1 (0.9%)

1 (1.6%)

  

16 (15.5%)

2 (3.3%)

 

PR

65 (63.1%)

8 (13.1%)

  

63 (61.2%)

12 (19.7%)

 

SD

29 (28.2%)

35 (57.4%)

  

16 (15.5%)

30 (49.1%)

 

PD

8 (7.8%)

17 (27.9%)

  

8 (7.8%)

17 (27.9%)

 

ORR

66 (64.1%)

9 (14.8%)

< 0.001

 

79 (76.7%)

14 (23.0%)

< 0.001

DCR

95 (92.2%)

44 (72.1%)

0.001

 

95 (92.2%)

44 (72.1%)

0.001

Intrahepatic Response

n = 103

n = 61

  

n = 103

n = 61

 

CR

1 (0.9%)

1 (1.6%)

  

18 (17.5%)

2 (3.3%)

 

PR

67 (65.1%)

9 (14.8%)

  

65 (63.1%)

13 (21.3%)

 

SD

31 (30.1%)

36 (59.0%)

  

16 (15.5%)

31 (50.8%)

 

PD

4 (3.9%)

15 (24.6%)

  

4 (3.9%)

15 (24.6%)

 

ORR

68 (66.0%)

10 (16.4%)

< 0.001

 

83 (80.6%)

15 (24.6%)

< 0.001

DCR

99 (96.1%)

46 (75.4%)

< 0.001

 

99 (96.1%)

46 (75.4%)

< 0.001

  1. CR, Complete response; PR, Partial response; SD, Stable disease; PD, Progressive disease; ORR, Objective responserate; DCR, Disease control rate
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us